Horsholm, Denmark- based LifeCycle Pharma A/S, has entered into three strategic collaboration agreements with leading players in the pharmaceutical industry:
1) Sandoz Inc. (an affiliate of Novartis AG) -- an exclusive development and commercialization agreement regarding the US market with respect to an undisclosed fenofibrate product developed by LifeCycle Pharma.
2) Merck Generics (a subsidiary of Merck KGaA of Darmstadt, Germany) -- an exclusive development and commercialization agreement regarding the European markets with respect to an undisclosed fenofibrate product developed by LifeCycle Pharma.
3) H. Lundbreck A/S -- an agreement by which Lundbeck is granted rights to LifeCycle Pharma's MeltDose(R) technology in connection with Lundbeck's further development of two internal pre-clinical CNS-related projects.
According to Dr. Flemming 0rnskov, President and CEO of LifeCycle Pharma:
Find more details of the collaboration agreements from the full press release."We are delighted to be able to announce strategic collaboration agreements with three such prominent global pharmaceutical companies. These new partnerships provide a strong validation of our innovative MeltDose(R) technology which improves the bioavailability of drugs with low water solubility.
They also validate our business model; a model based on identifying and developing products which represent significant business opportunities for big pharmaceutical companies. We are now also a significant step closer to the first commercial launch of a product derived from LifeCycle Pharma's strong research and development pipeline."
.jpg)
Comment Preview